CITED2

Across TCGA pan-cancer cohorts, CITED2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CITED2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CITED2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CITED2 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where CITED2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CITED2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	−0.991	<.001	8	view →
LUAD	Male	II,III,IV	−0.449	<.001	8	view →
LSCC	Male	All	−0.529	<.001	7	view →
CCRCC	Male	All	+0.261	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CITED2–HNSC

Open the HNSC breakdown →